In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
The European Commission’s Pharmaceutical Strategy for Europe calls for a structured dialogue to identify vulnerabilities in the pharma supply chain and provide policy options to strengthen medicines supply in the EU, including reducing EU...
In 2020, the FDA approved 53 new molecular entities (NMEs), the second highest level of NMEs approved in a given year in the past decade and over the 48 approvals in 2019. What drugs were approved, and what was the mix between small molecules and...
The COVID-19 pandemic has obliged a re-evaluation of manufacturing networks and supply lines. An upcoming DCAT webinar, Pharma’s Manufacturing and Supply Lines: New Ways for Risk Mitigation Post COVID-19, provides thought leadership on what...
The CDMO industry enters 2021 in the strongest position it has ever been in. The industry has reaped substantial benefits from government responses to the COVID-19 pandemic, especially those measures meant to maintain economic activity, but size...
COVID-19 will continue to be a defining issue for the pharmaceutical industry in 2021 as new vaccines and treatments enter the market. Across the broader industry, oncology drugs continue to be a major growth driver, the industry’s late-stage...
The most important developments impacting the biopharma industry and bioprocessing in 2021 are COVID-19-related as vaccine and therapeutic development and biomanufacturing continue at a rapid pace. The pandemic is also accelerating other trends:...
Having received emergency use authorization from the FDA for their COVID-19 vaccine, Pfizer and BioNTech reached a significant milestone in an unprecedented effort to develop a safe and effective vaccine under accelerated timelines. What was their...
What were the key moves made by CDMOs/CMOs in 2020? Expansion activity was robust in biologic drug-substance and drug-product manufacturing, in part due to COVID-19-related projects, but other manufacturing segments had activity too. DCAT Value...
Improvements in raw material inputs are necessary in order to deploy cell & gene therapies economically and at scale. Watch an on-demand webinar featuring Avantor experts to learn about challenges associated with using non-GMP raw materials, as...
Following the adoption of the European Commission’s Pharmaceutical Strategy for Europe late last month, EU policy makers are moving forward with ways to address vulnerabilities in the global drug supply chain arising from the COVID-19 pandemic by...
